Steroid refractory dermatomyositis following combination dabrafenib and trametinib therapy

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

152 Downloads (Pure)

Abstract

Rheumatology key message:

Autoimmune events may arise following therapy with MAPK/ERK pathway inhibitors.

Original language	English
Journal	Rheumatology (Oxford)
Early online date	30 Mar 2018
DOIs	https://doi.org/10.1093/rheumatology/key080
Publication status	E-pub ahead of print - 30 Mar 2018

Harrison_et_al_Steroid_refractory_dermatomyositis_Rheumatology_2018
Checked for eligibility: 20/02/2018 This is a pre-copyedited, author-produced version of an article accepted for publication in Rheumatology following peer review. The version of record Stephanie R Harrison, Alice Tew, Neil Steven, Benjamin A Fisher; Steroid refractory dermatomyositis following combination dabrafenib and trametinib therapy, Rheumatology is available online at: https://doi.org/10.1093/rheumatology/key080
Accepted author manuscript, 125 KBLicence: None: All rights reserved

@article{d956afd390a741dba9133f4cfc893c11,

title = "Steroid refractory dermatomyositis following combination dabrafenib and trametinib therapy",

abstract = "Rheumatology key message: Autoimmune events may arise following therapy with MAPK/ERK pathway inhibitors.",

author = "Stephanie Harrison and Alice Tew and Neil Steven and Benjamin Fisher",

year = "2018",

month = mar,

day = "30",

doi = "10.1093/rheumatology/key080",

language = "English",

journal = "Rheumatology (Oxford)",

issn = "1462-0324",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Steroid refractory dermatomyositis following combination dabrafenib and trametinib therapy

AU - Harrison, Stephanie

AU - Tew, Alice

AU - Steven, Neil

AU - Fisher, Benjamin

PY - 2018/3/30

Y1 - 2018/3/30

N2 - Rheumatology key message: Autoimmune events may arise following therapy with MAPK/ERK pathway inhibitors.

AB - Rheumatology key message: Autoimmune events may arise following therapy with MAPK/ERK pathway inhibitors.

U2 - 10.1093/rheumatology/key080

DO - 10.1093/rheumatology/key080

M3 - Article

SN - 1462-0324

JO - Rheumatology (Oxford)

JF - Rheumatology (Oxford)

ER -